Silo Pharma, Inc.

Silo Pharma (SILO) has logged zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in the recent period. However, low signal in a 90-day window does not indicate low risk; the biotech sector carries structural financing and dilution pressures that require deeper analysis. The full $49 Report extends coverage to 12 months of filings, maps the complete financing history, calculates dilution risk scores, and surfaces AI-detected risk signals that routine screening misses. The full $49 Report adds quantified dilution trajectory, 8-K context and timing analysis, institutional financing patterns, and AI risk modeling across executive stability and cash runway.